10-K: Carisma Therapeutics Inc. Announces Strategic Shift, Prioritizing Novel CAR-Monocyte Therapy

Carisma Therapeutics Inc. is focusing its clinical development on CT-0525, a novel CAR-Monocyte therapy, while suspending new patient enrollment in its CT-0508 trial and pausing CT-1119 development.

Summary

• Carisma Therapeutics Inc. is a clinical-stage cell therapy company focused on developing immunotherapies using its proprietary CAR-M platform.
• The company is prioritizing its follow-on product candidate, CT-0525, a CAR-Monocyte therapy for solid tumors overexpressing HER2, and expects to treat the first patient in the second quarter of 2024.
• CT-0525 utilizes a novel approach by engineering patients' monocytes directly, without ex vivo differentiation into macrophages, and has the potential for improved anti-tumor effects.
• The company is suspending new patient enrollment in its CT-0508 clinical trial and pausing further development of CT-1119, a mesothelin-targeted CAR-Monocyte, to focus resources on CT-0525.
• Carisma will continue its in vivo mRNA/LNP CAR-M programs in partnership with Moderna.
• The company is also pursuing early research and development of assets for diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases.
• As of December 31, 2023, the company had $77.6 million in cash and cash equivalents, which it believes will fund operations into the third quarter of 2025.
• The company has implemented a revised operating plan to reduce expenses and extend its cash runway, including a 37% reduction in its workforce.

Sentiment

Score: 4

Explanation: The document indicates a strategic shift with a focus on a promising new therapy (CT-0525) but also includes negative aspects such as a workforce reduction, suspension of a clinical trial, and pausing of another product candidate. The company's financial position is also a concern, requiring additional funding.

Positives

• The company is focusing on a novel CAR-Monocyte approach with CT-0525, which has the potential for improved anti-tumor effects.
• The company has received FDA clearance for its IND for CT-0525, allowing it to proceed with clinical trials.
• The company has a strategic collaboration with Moderna for in vivo CAR-M therapies.
• The company is exploring opportunities beyond oncology, including fibrosis and other immunologic and inflammatory diseases.
• The company has taken steps to reduce operating expenses and extend its cash runway.

Negatives

• The company is suspending new patient enrollment in its CT-0508 clinical trial.
• The company is pausing further development of CT-1119.
• The company has implemented a 37% reduction in its workforce.
• The company has incurred significant losses since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future.

Risks

• The company is heavily dependent on the success of CT-0525, which requires significant clinical testing before potential commercialization.
• The company will need substantial additional funding for its continuing operations, and if it is unable to raise additional capital, it may be forced to delay or eliminate its development programs.
• Cell therapy is a rapidly evolving area of science, and the approach the company is taking may not lead to approved or marketable products.
• The company relies on third parties to conduct clinical trials and manufacturing, which may not perform satisfactorily.
• The company may not be able to obtain, maintain, and enforce patent protection for its technology and product candidates.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future. The company believes that its current cash and cash equivalents will be sufficient to fund operations into the third quarter of 2025. The company plans to pursue additional financing and collaboration opportunities to support development of its product candidates and other research and development programs.

Management Comments

• The company is prioritizing its clinical development efforts on high potential value programs with meaningful near-term milestones while managing its expense allocation.
• The company believes that CT-0525 has favorable attributes compared to CT-0508, and that the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage.

Industry Context

The company is operating in the competitive biopharmaceutical industry, particularly in the rapidly evolving field of cell therapy. The company's CAR-M platform is a novel approach that aims to address the limitations of other cell therapies in treating solid tumors. The company faces competition from other companies developing engineered myeloid cell therapies, as well as autologous and allogeneic T cell therapies, NK cell therapies, and direct in vivo reprogrammed cell therapies.

Comparison to Industry Standards

• Carisma's approach of using engineered macrophages and monocytes is differentiated from the more common CAR-T and CAR-NK cell therapies.
• Companies like Myeloid Therapeutics, Shoreline Biosciences, and Inceptor Bio are also developing engineered myeloid cell therapies, making this a competitive space.
• The company's focus on solid tumors is a key differentiator, as many cell therapies have primarily targeted hematologic malignancies.
• The company's collaboration with Moderna for in vivo CAR-M therapies is a unique approach in the cell therapy space.
• The company's decision to prioritize CT-0525 and suspend enrollment in CT-0508 reflects a strategic shift towards a potentially more effective therapy.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a collaboration and license agreement with Moderna, a significant shareholder.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the strategic shift and financial challenges.
• Employees have been impacted by the reduction in workforce.
• Patients may benefit from the company's focus on CT-0525, a potentially more effective therapy.
• The company's collaboration with Moderna may lead to new treatment options for patients.

Next Steps

• The company expects to treat the first patient in the CT-0525 clinical trial in the second quarter of 2024.
• The company will continue its in vivo mRNA/LNP CAR-M programs in partnership with Moderna.
• The company will pursue additional financing and collaboration opportunities to support development of its product candidates and other research and development programs.

Key Dates

Keywords

CAR-M, cell therapy, immunotherapy, CT-0525, CT-0508, CT-1119, Moderna, HER2, monocyte, macrophage, oncology, clinical trial, mRNA, LNP, fibrosis